MBRX
- Moleculin Biotech, Inc.
()
Overview
Company Summary
Moleculin Biotech, Inc. (MBRX) is a biopharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of various types of cancer and other serious diseases. The company utilizes cutting-edge molecular and chemotherapeutic approaches to develop its pipeline of potential drug candidates.
MBRX's primary focus is on developing targeted therapies that can disrupt key processes involved in the growth and spread of cancer cells. By targeting specific molecular pathways and biological processes, their drugs aim to inhibit tumor growth, metastasis, and the development of drug resistance.
The company's drug candidates include compounds such as Annamycin, WP1066, WP1220, and WP1122. Annamycin is being developed to address chemotherapy-resistant forms of acute myeloid leukemia (AML), a type of blood cancer. WP1066 targets an oncogenic signaling pathway implicated in various types of tumors, including glioblastoma multiforme (GBM), pancreatic cancer, and leukemia.
MBRX is also developing WP1220, a potential treatment for cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma affecting the skin. WP1122, another drug candidate, is being investigated for the potential treatment of brain tumors.
In addition to its drug development efforts, MBRX conducts rigorous preclinical studies and engages in strategic collaborations with research institutions and other industry partners. These collaborations help leverage scientific expertise and resources to advance their drug candidates through clinical trials and potential regulatory approval processes.
Overall, Moleculin Biotech, Inc. is committed to developing innovative therapies aimed at improving the lives of patients by addressing unmet medical needs in the field of oncology and other serious diseases.